Emergent BioSolutions Inc (FRA:ER4)
€ 5.57 -0.242 (-4.16%) Market Cap: 301.09 Mil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 0.49 GF Score: 74/100

Emergent BioSolutions Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 07:00PM GMT
Release Date Price: €28.98 (-1.78%)
Unidentified Analyst

(technical difficulty) Bob Burrows, Vice President of Investor Relations; and Rich Lindahl, our Chief Financial Officer.

For those of you that don't know, Emergent BioSolutions is a kind of a global biopharmaceutical company that is specialized in kind of public health threats and combating public health threats. And with that, I'll go ahead and turn over to Rich, I don't know if you want to do an introduction or just kind of an overview and maybe talk about some of the recent events, and then we get into more of the dialogue here.

Richard S. Lindahl
Emergent BioSolutions Inc. - Executive VP, CFO & Treasurer

Sure. So thank you very much for having us. I appreciate it. Yes, as Larry said, we're a company that focuses on providing solutions to public health reps, whether they be kind of naturally, accidentally or deliberately occurring.

To that end, we have a suite of products and services, which we'll talk about in more detail as we go through the conversation centered around vaccines, therapeutics and drug-device

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot